When a private company first sells shares to the public on a stock exchange.
IPO process: file prospectus with regulators, set price range, build book with investor demand, price and list. First-day "pop" common but doesn't guarantee long-term performance. Many IPOs underperform the broader market over several years post-listing.
When a private company first sells shares to the public on a stock exchange. IPO process: file prospectus with regulators, set price range, build book with investor demand, price and list. First-day "pop" common but doesn't guarantee long-term performance. Many IPOs underperform the broader market over several years post-listing.
In corporate actions, IPO (Initial Public Offering) is one of the building blocks investors use to compare opportunities and assess risk. Understanding it helps you read research notes, earnings reports, and market commentary without getting lost in jargon.
IPO process: file prospectus with regulators, set price range, build book with investor demand, price and list. First-day "pop" common but doesn't guarantee long-term performance.
IPO grey market premium (GMP) reveals investor sentiment before listing, but it's unregulated and often misused by retail investors chasing quick gains.
May 14, 2026
The Quick Take * Cerebras reportedly raising IPO price range to $150–$160 per share, signalling strong oversubscription * Surge in investor demand driving the upward revision from the initial filing range * No analyst or institutional commentary available yet; sources cited are unnamed insiders * Final IPO pricing and trading debut expected imminently following the revised range announcement * Strong AI-chip IPO demand in the US could lift sentiment for semiconductor plays in Asia includin
May 14, 2026
The Quick Take * Cerebras plans to lift its IPO price range to $150–$160 per share, up from a prior range, per sources * Surging investor demand is driving the upward revision ahead of the company's public listing * No analyst or institutional commentary cited in available coverage; story sourced exclusively via Investing.com * Final IPO pricing and trading debut are the next key milestones to watch as bookbuilding closes * A high-profile AI chip IPO at elevated valuation signals continued
May 14, 2026
The Quick Take * Siemens Healthineers lowered its full-year guidance due to underperformance in its diagnostics division * China's healthcare reforms are hitting the diagnostics segment harder than anticipated, triggering the profit warning * Management is actively reviewing strategic options including a full sale or separate IPO of the diagnostics unit * Potential buyers have already emerged as interested parties, signalling M&A process may be advanced * A diagnostics divestiture could re
May 11, 2026
Looking for more financial terms?
Browse Full Glossary →